<DOC>
	<DOCNO>NCT01260818</DOCNO>
	<brief_summary>Tranexamic acid show reduce postoperative blood loss transfusion requirement number type surgery . Most trial orthopedic surgery conduct intravenously arthroplasty , hip fracture spine surgery . This study would aim see effect topical use tranexamic acid reduction blood loss transfusion total hip arthroplasty</brief_summary>
	<brief_title>Topical Application Tranexamic Acid Reduces Postoperative Blood Loss Total Hip Arthroplasty</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Postoperative Hemorrhage</mesh_term>
	<mesh_term>Tranexamic Acid</mesh_term>
	<criteria>Patient undergo elective total hip arthroplasty . Must primary arthroplasty . Must singleside arthroplasty . Must old 18 year . Cemented arthroplasty . Patients platelet count less 100 , 000/mm3 history thrombocytopenia . Patients know coagulopathy ( APTT PT outside normal range preoperatively ) . Patients past medical history thrombiembolism time . Patients anemia ( hemoglobin level less 8 mg/dl hematocrit &lt; 24 % ) . Patients document DVT PE screen past three month . Patients know hypersensitivity tranexamic acid . constituent product . Patients associated major illness ( e.g. , severe cardiac [ New York Heart Association Class III IV ] respiratory disease ) . Anticoagulants ( LMWH heparin prophylactic dos prevent deep vein thrombosis ) , direct thrombin inhibitor thrombolytic therapy administer complete within last week . Jehovah 's Witnesses , group patient ethical objection receive blood product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Tranexamic Acid</keyword>
</DOC>